| Literature DB >> 30559372 |
Lun Suo1, Yu Xiao Zhou2, Li Ling Jia2, Hai Bo Wu3, Jin Zheng2, Qi Feng Lyu3, Li Hua Sun3, Han Sun4, Yan Ping Kuang5.
Abstract
There exist some patients who face recurrent total fertilization failure during assisted reproduction treatment, but the pathological mechanism underlying is elusive. Here, by using sc-RNA-seq method, the transcriptome profiles of ten abnormally fertilized zygotes were assessed, including five zygotes from one patient with recurrent Poly-PN zygotes, and five zygotes from a patient with pronuclear fusion failure. Four zygotes with three pronuclear (Tri-PN) were collected from four different patients as controls. After that, we identified 951 and 1697 significantly differentially expressed genes (SDEGs) in Poly-PN and PN arrest zygotes, respectively as compared with the control group. KEGG analyses indicated down regulated genes in the Poly-PN group included oocyte meiosis related genes, such as PPP2R1B, YWHAZ, MAD2L1, SPDYC, SKP1 and CDC27, together with genes associated with RNA processing, such as SF3B1, LOC645691, MAGOHB, PHF5A, PRPF18, DDX5, THOC1 and BAT1. In contrast, down regulated genes in the PN arrest group, included cell cycle genes, such as E2F4, DBF4, YWHAB, SKP2, CDC23, SMC3, CDC25A, CCND3, BUB1B, MDM2, CCNA2 and CDC7, together with homologous recombination related genes, such as NBN, XRCC3, SHFM1, RAD54B and RAD51. Thus, our work provides a better understanding of transcriptome profiles underlying RTFF, although it based on a limited number of patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30559372 PMCID: PMC6297154 DOI: 10.1038/s41598-018-36275-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Embryonic developmental consequence of the patients with RTFF during assisted reproduction treatment.
| Clinical cycles | Patient with recurred Poly-PN zygotes | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oocyte | Oocyte | Fertilization | |||||||
| MII | MI | GV | Abnormal | 0PN | Poly-PN | ||||
| 1st | HMG+MPA+EE | ICSI | 11 | 5 | 3 | 2 | 1 | 1 | 4 |
| 2nd | HMG+MPA+CC | ICSI | 7 | 6 | 0 | 1 | 0 | 1 | 5 |
| Patient with recurred PN-arrest zygotes | |||||||||
| Oocyte | Fertilization | ||||||||
| Total | MII | MI | GV | Abnormal | 2PN | PN arrest | |||
| 1st | Short protocol | IVF/ICSI | 19 | 9/9 | 0 | 0 | 1 | 9/9 | 18 |
| 2nd | HMG + MPA | ICSI | 8 | 7 | 0 | 0 | 1 | 7 | 7 |
| 3rd | HMG + CC | ICSI | 10 | 9 | 0 | 1 | 0 | 9 | 9 |
Figure 1Overview of the scRNA-seq experimental design.
Figure 2Transcriptome profile of the Poly-PN and PN-arrest zygotes. (a) The number of reference transcripts averagely found in each sample in different groups based on clustering of expression patterns for 14 single cell samples from Poly-PN, PN arrest and Control groups; (c,d) Scatterplot showing the number of genes up regulated (red) and down regulated (blue) in Poly PN (c) and PN arrest zygotes (d) separately compared with control group.
KEGG Signaling pathways enrichment of SDEGs up regulated in Poly-PN and PN arrest groups separately compared with controls.
| Items | Count | % | Genes | ||
|---|---|---|---|---|---|
| SDEGs (Poly-PN/Control) | Ribosome | 12 | 5.5 | 5.80E-09 | RPSA, RPL23, RPL9, RPL35, RPL3, RPS9, RPL7A, RPS11, RPS20, RPS4X, RPS8, RPS24 |
| Huntington’s disease | 8 | 3.6 | 6.40E-03 | POLR2F, TAF4, EP300, NDUFB8, NDUFA6, CREBBP, UQCRQ, ATP5J | |
| Wnt signaling pathway | 7 | 3.2 | 1.00E-02 | PRKCA, CTBP1, TCF7, EP300, CREBBP, FRAT1, FRAT2 | |
| Pathway in cancer | 10 | 4.5 | 1.90E-02 | PRKCA, CTBP1, TCF7, EP300, RALBP1, CREBBP, FOXO1, LAMC1, IKBKB, LAMB1 | |
| Spliceosome | 6 | 2.7 | 1.90E-02 | CHERP, PCBP1, LSM7, SNRPD2, SNRPG, SF3B2 | |
| Notch signaling pathway | 4 | 1.8 | 2.00E-02 | CTBP1, EP300, PSEN2, CREBBP | |
| Prostate cancer | 5 | 2.3 | 2.40E-02 | TCF7, EP300, CREBBP, FOXO1, IKBKB | |
| SDEGs (PN arrest/Control) | Ribosome | 56 | 28.1 | 1.10E-84 | RPL36A, RPL19, RPL13, RPLP2, RPS2, RPS3, RPS3A, RPLP0, RPLP1, RPL10, RPL12, RPS27A, RPS4X, RPS18, RPS19, RPL41, RPS16, RPS17, RPS15, RPS12, RPS13, RPS11, UBA52, RPL35, RPS15A, RPL36, RPL37, RPL38, RPS25, RPL30, RPS27, RPS28, RPL32, RPS29, RPL31, RPL8, RPL3, RPL10A, RPL7A, RPL4, RPS20, RPS21, RPS23, RPS24, RPL26, RPS9, RPL27, RPL23A, RPL24, RPS5, RPL28, RPL29, RPL23, RPL13A, RPL37A |
| Oxidative phosphorylation | 11 | 5.5 | 5.20E-05 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, ATP5L, COX6C, NDUFA11, NDUFB2 | |
| Parkinson’s disease | 9 | 4.5 | 1.20E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 | |
| Alzheimer’s disease | 9 | 4.5 | 5.50E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 | |
| Huntington’s disease | 9 | 4.5 | 9.90E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 |
KEGG Signaling pathways enrichment of SDEGs down regulated in Poly-PN and PN arrest groups separately compared with controls.
| Items | Count | % | Genes | ||
|---|---|---|---|---|---|
| SDEGs (Poly-PN/Control) | Citrate cycle (TCA cycle) | 6 | 0.9 | 0.0038 | LOC642502, DLST, SUCLG1, DLD, PDHA2, FH |
| Spliceosome | 12 | 1.7 | 0.004 | SFRS7, SF3B1, LOC645691, MAGOHB, PHF5A, HNRNPC, PRPF18, DDX5, SF3B4, PRPF38A, THOC1, BAT1 | |
| Pyrimidine metabolism | 9 | 1.3 | 0.016 | POLR2H, UMPS, POLR2E, RRM2, PNPT1, DCK, ZNRD1, POLR2D, DUT | |
| N-Glycan biosynthesis | 6 | 0.9 | 0.02 | TUSC3, ALG3, DPM1, ALG6, MGAT5, ALG13 | |
| Basal transcription factors | 5 | 0.7 | 0.031 | TAF9B, GTF2A1L, GTF2B, TBPL1, GTF2H1 | |
| Oocyte meiosis | 9 | 1.3 | 0.036 | PPP2R1B, YWHAZ, MAD2L1, CCNB2, PPP2CA, FBXO5, SKP1, CDC27, SPDYC | |
| Ubiquitin mediated proteolysis | 10 | 1.4 | 0.047 | UBE2N, UBE2E3, UBE2D3, UBA3, UBE2W, PIAS1, SKP1, UBOX 5, TRAF6, CDC27 | |
| SDEGs (PN arrest/Control) | Basal transcription factors | 8 | 0.6 | 4.20E-03 | TAF11, GTF2E1, GTF2I, TAF4B, GTF2F2, TAF9B, GTF2B, GTF2H1 |
| Cell cycle | 16 | 1.1 | 7.60E-03 | CDC7, E2F4, DBF4, YWHAB, SKP2, CDC23, ANAPC10, SMC3, CDC25A, ORC2L, CCND3, ORC4L, BUB1B, ORC5L, MDM2, CCNA2 | |
| Ubiquitin mediated proteolysis | 17 | 1.2 | 7.70E-03 | UBE2G1, SKP2, CDC23, UBE2F, ANAPC10, UBE2H, UBE2C, BIRC2, BRCA1, UBE2E3, TRIM32, UBA3, UBE2W, MDM2, PIAS2, RCHY1, TRAF6 | |
| Proteasome | 8 | 0.6 | 2.10E-02 | PSMA1, PSMC6, PSMD12, PSMA4, PSMC1, SHFM1, PSMA7, PSMD7 | |
| Homologous recombination | 6 | 0.4 | 2.40E-02 | NBN, XRCC3, RAD51L1, SHFM1, RAD54B, RAD51 | |
| O-Glycan biosynthesis | 6 | 0.4 | 3.10E-02 | GALNT3, GALNT1, C1GALT1C1, GALNT11, GCNT1, C1GALT1 | |
| Amino sugar and nucleotide sugar metabolism | 7 | 0.5 | 4.60E-02 | GNPDA1, GNPDA2, HEXB, UGDH, NAGK, FPGT, UGP2 |
Figure 3Relative expression levels of SDEGs specifically expressed in Poly-PN and or PN arrest zygotes. (a) The Venn diagram of down regulated SDEGs in Poly-PN and PN arrest groups separately compared with those in control group; (b–e) Scatterplot showing the relative expression levels of the particularly interesting SDEGs specifically down regulated in Poly-PN or PN arrest zygotes. P < 0.001 was indicated significantly different.
Figure 4(a,b) Validation of two meiosis ralated genes in mice oocytes using gene knock down experiment. (c) Comparative expression of these identified genes during fertilization in human (bottom layer) and mice (up layer), respectively. HR, Homologous recombination.
Figure 5Module visualization of Poly-PN and PN arrest specifically down regulated SDEGs. Module visualization of Poly-PN and PN arrest specifically down regulated SDEGs. Down regulated SDEGs were shown Poly-PN specifically (left panel) PN arrest specifically (right panel) and genes down regulated overlap in both of this two groups (middle panel), PM, Pyrimidine metabolism; HR, Homologous recombination; ASNSM, Amino sugar or nucleotide sugar metabolism.